Cantor Fitzgerald’s Mereo BioPharma MREO Stock Holding History

Cantor Fitzgerald’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-110,000	Closed	-$227K	–	308
2025 Q3	$227K	Sell	110,000 -232,957	-68%	-$429K	﹤0.01%	357
2025 Q2	$929K	Sell	342,957 -12,043	-3%	-$29.1K	0.02%	165
2025 Q1	$799K	Buy	355,000 +130,000	+58%	+$368K	0.02%	125
2024 Q4	$788K	Buy	+225,000	New	+$884K	0.02%	97
2024 Q3	–	Sell	-275,000	Closed	-$990K	–	269
2024 Q2	$990K	Buy	+275,000	New	+$891K	0.2%	75

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Cantor Fitzgerald's MREO Position: Q4 2025 in Review

Cantor Fitzgerald sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 110,000 shares — an estimated $227K sold.

Cantor Fitzgerald first reported a position in MREO in Q2 2024 and held it in 5 quarters. The position peaked at $990K in Q2 2024. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

Cantor Fitzgerald reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
Cantor Fitzgerald sold 110,000 Mereo BioPharma shares in Q4 2025, an estimated $227K.
Cantor Fitzgerald first reported a position in Mereo BioPharma in Q2 2024 and held it in 5 quarters.
Cantor Fitzgerald's Mereo BioPharma position peaked at $990K in Q2 2024.
70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.